Propranolol e inyecciones intravítreas de ranibizumab en el desprendimiento seroso macular secundario a hemangioblastoma retiniano capilar

Hernández-Martínez, P.; Gallego-Pinazo, Roberto; Dolz-Marco, Rosa; Arévalo, J. Fernando; Díaz-Llopis, M.; Lanuza, Á. Cisneros

doi:10.1016/j.oftal.2014.01.007

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strong efficacy of propranolol as a single agent against other vascular tumor types has been reported for infantile hemangioma [ 28 , 29 ], Kaposi's sarcoma [ 30 ], hemangioendothelioma [ 31 - 33 ], and hemangioblastoma [ 34 - 36 ]. Regardless of convention therapy, almost all patients will succumb to cardiac angiosarcoma within a year of diagnosis [ 14 - 18 ], and for patients who cannot or choose not to undergo surgery, chemotherapy, and/ or radiation, supportive care has historically remained their only remaining option.…”

Section: Discussionmentioning

confidence: 99%

Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment

2018

View full text Add to dashboard Cite

Angiosarcoma is the most common malignant cardiac tumor. Cardiac angiosarcoma is a highly lethal neoplasm that is largely resistant to conventional anti-cancer therapy. Mean survival of patients with cardiac angiosarcoma is only 4 months, and almost all patients will succumb to the disease within 1 year. The beta blocker propranolol is an emerging therapy against angiosarcoma. When combined with conventional therapies, propranolol increases progression free and overall survival in patients with this tumor type. It is currently unknown if propranolol is capable of showing anti-cancer efficacy as a single agent therapy. We report a case of a 61 year old woman diagnosed with primary cardiac angiosarcoma and liver and lung metastases. This patient chose to decline conventional therapy, and instead was prescribed the beta blocker propranolol as a single agent treatment. After 12 months, the mediastinal mass substantially debulked and decreased in size, and the metastatic nodules stabilized or resolved with no evidence of hyper-metabolic activity on PET-CT. This is the first reported data showing long term efficacy of the beta blocker propranolol as a single agent therapy against angiosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment

2018

View full text Add to dashboard Cite

show abstract

“… 2 One treatment approach involves injecting anti-VEGF into the vitreous: which bathes the tumor in diluted anti-VEGF vitreous fluid. 3 Alternatively, ophthalmic artery chemosurgery may provide an advantage by: 1. delivering almost 1000 times the dose of anti-VEGF agent compared to an intravitreous injection; and 2. delivering drug to the ophthalmic artery which presumably feeds directly into the aberrant blood vessels of the hemangioblastoma.…”

Section: Discussionmentioning

confidence: 99%

“…Many tumors are recalcitrant to treatment including intravitreous injections of steroids or anti-vasogenic endothelial growth factor (VEGF), cryotherapy, radiation and laser, including photodynamic therapy. 1 , 2 , 3 , 4 , 5 It is not uncommon for these eyes to progress to blindness due to exudation, tractional retinal changes, or neovascular glaucoma; and it has been predicted that 25% of eyes will be rendered permanently blind (vision less than 20/400). 2 , 6 An alternative form of management to halt the progression of disease, maintain vision and provide ocular salvage is explored in this case report.…”

Section: Introductionmentioning

confidence: 99%

Treatment of juxtapapillary hemangioblastoma by intra-arterial (ophthalmic artery) chemotherapy with bevacizumab

Francis

Slakter

Abramson

et al. 2018

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

PurposeTo report on two cases of treatment-refractory juxtapapillary hemagioblastomas that were managed with intra-arterial bevacizumab delivered via the ophthalmic artery.ObservationsCase 1 is a 35 year-old man with juxtapapillary hemangioblastoma who continued to have progressive tractional retinal detachment, optic nerve neovascaularization and cystoid macula edema (CME) despite heavy prior treatment with intravitreal anti-vascular endothelial growth factor (VEGF) and steroid intravitreal injections and laser. Case 2 is a 41 year-old woman with juxtapapillary hemangioblastoma who had progressive tractional retinal detachment, CME and visually-threatening intraocular pressure elevation despite treatment with anti-VEGF injection and laser. Both cases were treated with three infusions of intra-arterial bevacizumab delivered via the ophthalmic artery. Both tumors demonstrated measurable decrease in height, stability of their secondary retinal changes and minimal requirement for additional treatment at 30 mos and 26 mos follow-up, respectively for cases 1 and 2.Conclusions and importanceThese cases suggest that higher-dose, targeted delivery of anti-VEGF to hemangioblastomas via ophthalmic artery injection may be useful in stabilizing the disease and abating the typical progression of secondary retinal pathology, at least in the first two years after treatment.

show abstract

Retinales kapilläres Hämangioblastom im makulopapillären Bündel

et al. 2021

View full text Add to dashboard Cite

Propranolol e inyecciones intravítreas de ranibizumab en el desprendimiento seroso macular secundario a hemangioblastoma retiniano capilar

Cited by 3 publications

References 5 publications

Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment

Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment

Treatment of juxtapapillary hemangioblastoma by intra-arterial (ophthalmic artery) chemotherapy with bevacizumab

Retinales kapilläres Hämangioblastom im makulopapillären Bündel

Contact Info

Product

Resources

About